<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="of Medical SciencesTehran, Iran aaem-8-e51 : Review Article Management of" exact="Pemphigus" post="in COVID-19 Pandemic Era; a Review Article AbdollahimajdFahimeh1Shahidi-DadrasMohammad1M RobatiReza12*DadkhahfarSahar1[1],"/>
 <result pre="several concerns have been raised by dermatologists as well as" exact="pemphigus" post="patients who take immunosuppressive drugs. In this paper, we"/>
 <result pre="paper, we review the literature about the common treatment of" exact="pemphigus" post="with a focus on the lessons from similar epidemics"/>
 <result pre="from similar epidemics to find a proper suggestion to manage" exact="pemphigus" post="in the COVID-19 pandemic era. The effect of many"/>
 <result pre="effect of many of the drugs used for treatment of" exact="Pemphigus" post="vulgaris (PV) on COVID-19 is not clear. We also"/>
 <result pre="also do not have data on the impact of this" exact="autoimmune disease," post="which may involve the mucous membranes, on the acquisition"/>
 <result pre="the population of susceptible patients suffering from auto-immune diseases like" exact="pemphigus" post="is essential. The evidence on best ways to manage"/>
 <result pre="and the data is updated every day. Key Words COVID-19" exact="pemphigus" post="severe acute respiratory syndrome coronavirus 2 therapy Introduction The"/>
 <result pre="data is updated every day. Key Words COVID-19 pemphigus severe" exact="acute" post="respiratory syndrome coronavirus 2 therapy Introduction The 2019 novel"/>
 <result pre="is updated every day. Key Words COVID-19 pemphigus severe acute" exact="respiratory" post="syndrome coronavirus 2 therapy Introduction The 2019 novel coronavirus"/>
 <result pre="updated every day. Key Words COVID-19 pemphigus severe acute respiratory" exact="syndrome" post="coronavirus 2 therapy Introduction The 2019 novel coronavirus (Severe"/>
 <result pre="syndrome coronavirus 2 therapy Introduction The 2019 novel coronavirus (Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) is spreading around the"/>
 <result pre="coronavirus 2 therapy Introduction The 2019 novel coronavirus (Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 [SARS-CoV-2]) is spreading around the world"/>
 <result pre="2 therapy Introduction The 2019 novel coronavirus (Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 [SARS-CoV-2]) is spreading around the world and"/>
 <result pre="[SARS-CoV-2]) is spreading around the world and has caused a" exact="pneumonia" post="outbreak originating in Wuhan, China. The disease was later"/>
 <result pre="has caused a pneumonia outbreak originating in Wuhan, China. The" exact="disease" post="was later named coronavirus disease 2019 (COVID-19) in February"/>
 <result pre="originating in Wuhan, China. The disease was later named coronavirus" exact="disease" post="2019 (COVID-19) in February 2020, by WHO (1). The"/>
 <result pre="resulting in severe illness and even death due to sepsis," exact="acute" post="respiratory distress syndrome (ARDS) and multi-organ failure (2). Pemphigus"/>
 <result pre="in severe illness and even death due to sepsis, acute" exact="respiratory" post="distress syndrome (ARDS) and multi-organ failure (2). Pemphigus vulgaris"/>
 <result pre="illness and even death due to sepsis, acute respiratory distress" exact="syndrome" post="(ARDS) and multi-organ failure (2). Pemphigus vulgaris is a"/>
 <result pre="sepsis, acute respiratory distress syndrome (ARDS) and multi-organ failure (2)." exact="Pemphigus" post="vulgaris is a potentially life-threatening autoimmune bullous disease affecting"/>
 <result pre="and multi-organ failure (2). Pemphigus vulgaris is a potentially life-threatening" exact="autoimmune" post="bullous disease affecting the skin and mucosa and is"/>
 <result pre="failure (2). Pemphigus vulgaris is a potentially life-threatening autoimmune bullous" exact="disease" post="affecting the skin and mucosa and is caused by"/>
 <result pre="a potentially life-threatening autoimmune bullous disease affecting the skin and" exact="mucosa" post="and is caused by autoantibodies directed against desmoglein 1"/>
 <result pre="and desmoglein 3 adhesion molecules of the epidermis (3, 4)." exact="Severe" post="cases of PV represent a true medical emergency (5)."/>
 <result pre="several concerns have been raised by dermatologists as well as" exact="pemphigus" post="patients who take immunosuppressive drugs. These concerns include the"/>
 <result pre="take immunosuppressive drugs. These concerns include the need for proper" exact="disease" post="control with minimal immune suppression to avoid possible fatal"/>
 <result pre="mechanisms in COVID-19 (e.g. cytokine release storm leading to interstitial" exact="pulmonary" post="inflammation, extensive lung damage and acute respiratory distress syndrome)"/>
 <result pre="storm leading to interstitial pulmonary inflammation, extensive lung damage and" exact="acute" post="respiratory distress syndrome) (6) could affect those auto-immune diseases"/>
 <result pre="leading to interstitial pulmonary inflammation, extensive lung damage and acute" exact="respiratory" post="distress syndrome) (6) could affect those auto-immune diseases such"/>
 <result pre="paper, we review the literature on the common treatments of" exact="pemphigus" post="with a focus on lessons from similar epidemics to"/>
 <result pre="from similar epidemics to find a proper suggestion to manage" exact="pemphigus" post="in the COVID-19 pandemic era. Systemic corticosteroids Historically, systemic"/>
 <result pre="proper suggestion to manage pemphigus in the COVID-19 pandemic era." exact="Systemic" post="corticosteroids Historically, systemic corticosteroids, usually oral prednisone alone or"/>
 <result pre="manage pemphigus in the COVID-19 pandemic era. Systemic corticosteroids Historically," exact="systemic" post="corticosteroids, usually oral prednisone alone or in combination with"/>
 <result pre="immunosuppressive drugs, have been used as the mainstay treatment in" exact="pemphigus" post="vulgaris (7). Although these agents have led to substantial"/>
 <result pre="concern becomes even more pronounced during the epidemic of some" exact="infectious" post="agents, including the coronavirus. Considering the effect of systemic"/>
 <result pre="some infectious agents, including the coronavirus. Considering the effect of" exact="systemic" post="corticosteroids on suppressing inflammation and the presence of lung"/>
 <result pre="of systemic corticosteroids on suppressing inflammation and the presence of" exact="lung inflammation" post="induced by host immune responses in influenza, SARS-CoV, MERS-CoV,"/>
 <result pre="been of interest to physicians during the outbreaks of these" exact="infections" post="(2, 12). Existing clinical data have not confirmed the"/>
 <result pre="not confirmed the beneficial effect of corticosteroids in treatment of" exact="respiratory" post="infections due to SARS-CoV, or MERS-CoV (12). The observational"/>
 <result pre="confirmed the beneficial effect of corticosteroids in treatment of respiratory" exact="infections" post="due to SARS-CoV, or MERS-CoV (12). The observational studies"/>
 <result pre="MERS-CoV (12). The observational studies had reported increased mortality and" exact="secondary" post="infection rates in influenza, impaired clearance of SARS-CoV and"/>
 <result pre="(12). The observational studies had reported increased mortality and secondary" exact="infection" post="rates in influenza, impaired clearance of SARS-CoV and MERS-CoV,"/>
 <result pre="SARS-CoV and MERS-CoV, and complications of corticosteroid therapy (e.g. diabetes," exact="avascular necrosis," post="and steroid-induced psychosis) in survivors (13, 14). Therefore, not"/>
 <result pre="only does the role of steroids in the treatment of" exact="acute" post="lung injury in these viral infections remain controversial, but"/>
 <result pre="steroids in the treatment of acute lung injury in these" exact="viral" post="infections remain controversial, but also this treatment may be"/>
 <result pre="in the treatment of acute lung injury in these viral" exact="infections" post="remain controversial, but also this treatment may be harmful"/>
 <result pre="also this treatment may be harmful in patients with 2019-nCoV" exact="infection" post="(12, 15). Currently, pandemic-related emotional stress, decreasing the dose"/>
 <result pre="harmful in patients with 2019-nCoV infection (12, 15). Currently, pandemic-related" exact="emotional" post="stress, decreasing the dose of immunosuppressive medications for fear"/>
 <result pre="immunosuppressive medications for fear of COVID-19 and eventually getting this" exact="infection" post="may be considered as exacerbating factors or triggers for"/>
 <result pre="infection may be considered as exacerbating factors or triggers for" exact="pemphigus" post="vulgaris (16). Therefore, strict adherence to health principles and"/>
 <result pre="vulgaris (16). Therefore, strict adherence to health principles and avoiding" exact="emotional" post="stress while continuing the treatment protocol recommended by dermatologists"/>
 <result pre="has resulted in higher remission rates, long term clinical response," exact="lower" post="incidence of serious adverse events and rapid prednisone tapering"/>
 <result pre="immunosuppressive therapies making its approval as a first-line therapy in" exact="pemphigus" post="possible (19). Rituximab is generally considered safe in patients"/>
 <result pre="possible (19). Rituximab is generally considered safe in patients with" exact="pemphigus" post="vulgaris and serious infections, while reported, are rare. Although"/>
 <result pre="including sepsis, have been reported following RTX treatment (21). Opportunistic" exact="infections" post="such as cytomegalovirus infection and Pneumocystis pneumonia (PCP), although"/>
 <result pre="been reported following RTX treatment (21). Opportunistic infections such as" exact="cytomegalovirus infection" post="and Pneumocystis pneumonia (PCP), although extremely rare and limited"/>
 <result pre="reported following RTX treatment (21). Opportunistic infections such as cytomegalovirus" exact="infection" post="and Pneumocystis pneumonia (PCP), although extremely rare and limited"/>
 <result pre="RTX treatment (21). Opportunistic infections such as cytomegalovirus infection and" exact="Pneumocystis pneumonia" post="(PCP), although extremely rare and limited to sporadic case"/>
 <result pre="treatment (21). Opportunistic infections such as cytomegalovirus infection and Pneumocystis" exact="pneumonia" post="(PCP), although extremely rare and limited to sporadic case"/>
 <result pre="cytomegalovirus infection and Pneumocystis pneumonia (PCP), although extremely rare and" exact="limited" post="to sporadic case reports, have been reported (22, 23)."/>
 <result pre="have been reported (22, 23). The risk of reactivation of" exact="hepatitis" post="B and C viruses as well as tuberculosis has"/>
 <result pre="reactivation of hepatitis B and C viruses as well as" exact="tuberculosis" post="has also been reported (17). It should be noted"/>
 <result pre="It should be noted that protective humoral immunity in the" exact="central nervous system" post="(CNS) requires peripheral CD19-dependent germinal center formation following neurotrophic"/>
 <result pre="protective humoral immunity in the central nervous system (CNS) requires" exact="peripheral" post="CD19-dependent germinal center formation following neurotrophic coronavirus infection (24)"/>
 <result pre="(CNS) requires peripheral CD19-dependent germinal center formation following neurotrophic coronavirus" exact="infection" post="(24) and there are evidence that show SARS-CoV-2 targets"/>
 <result pre="host cell-surface receptor for SARS-CoV-2 envelope spike glycoprotein) in the" exact="brain" post="has been proposed, the exact mechanism of CNS involvement"/>
 <result pre="SARS-CoV-2 has not been identified, the potential risks of treating" exact="pemphigus" post="with rituximab should be taken into account. Special attention"/>
 <result pre="monitoring of the patients and tapering concurrent corticosteroids to minimize" exact="susceptibility to" post="life-threatening infections. This risk should be weighed against the"/>
 <result pre="the prominent and effective role of RTX in treatment of" exact="pemphigus" post="and reducing the number of follow up visits (19)."/>
 <result pre="mycophenolate mofetil (MMF) as first-line steroid-sparing agents for treatment of" exact="pemphigus" post="rather than other adjuvant immunosuppressants (18). Nevertheless, different variables"/>
 <result pre="of COVID-19. It is noteworthy that there are reports of" exact="atypical" post="presentation of Middle East respiratory syndrome virus (MERS-CoV) in"/>
 <result pre="that there are reports of atypical presentation of Middle East" exact="respiratory" post="syndrome virus (MERS-CoV) in patients who received immunosuppressive drugs;"/>
 <result pre="there are reports of atypical presentation of Middle East respiratory" exact="syndrome" post="virus (MERS-CoV) in patients who received immunosuppressive drugs; therefore,"/>
 <result pre="who received immunosuppressive drugs; therefore, careful monitoring of patients for" exact="atypical" post="symptoms should be taken into account (27). The administration"/>
 <result pre="for COVID-19 (6) but data are scarce and controversial. In" exact="pemphigus" post="patients with COVID-19 and flare of PV, this therapeutic"/>
 <result pre="s thromboembolism in severely ill patients (30). Recommendations Patients with" exact="pemphigus" post="need proper treatment for their underlying condition; however, during"/>
 <result pre="of COVID-19, these patients may carry the risk of severe" exact="infections" post="with disastrous outcomes. Figure 1 is a proposed algorithm"/>
 <result pre="1 is a proposed algorithm for management of patients with" exact="pemphigus" post="during the COVID-19 outbreak based on the former consensus"/>
 <result pre="COVID-19 outbreak based on the former consensus on treatment of" exact="pemphigus" post="and the current evidence on COVID-19. The following issues"/>
 <result pre="in using recommended precautions and proper ethical teledermatology practice (31)." exact="Psychological" post="tolerance of patients during quarantine, especially in those who"/>
 <result pre="cases of drug discontinuation without reasonable indication. Patients with milder" exact="disease" post="can be treated less aggressively with local steroids (topical"/>
 <result pre="PV patients, respectively. Figure1 The proposed algorithm for management of" exact="pemphigus" post="patients during the outbreak of COVID-19. Off all systemic"/>
 <result pre="of pemphigus patients during the outbreak of COVID-19. Off all" exact="systemic" post="therapies: the patient has not been taking any systemic"/>
 <result pre="all systemic therapies: the patient has not been taking any" exact="systemic" post="therapy for at least 2 months. Minimal therapy: the"/>
 <result pre="adjuvant therapy and/or topical corticosteroids for at least 2 months)." exact="Partial" post="remission: There are transient lesions that heal within a"/>
 <result pre="corticosteroids for at least 2 months). Partial remission: There are" exact="transient" post="lesions that heal within a week without additional treatment."/>
 <result pre="transient lesions that heal within a week without additional treatment." exact="Complete" post="remission: There is no stable or new lesion. Relapse:"/>
 <result pre="a week without additional treatment. Complete remission: There is no" exact="stable" post="or new lesion. Relapse: The extension of stable lesion(s)"/>
 <result pre="is no stable or new lesion. Relapse: The extension of" exact="stable" post="lesion(s) and/or the development of â‰¥ 3 new lesions"/>
 <result pre="the population of susceptible patients suffering from auto-immune diseases like" exact="pemphigus" post="is essential. Many patients with PV may present to"/>
 <result pre="effect of many of the drugs used for treatment of" exact="Pemphigus" post="vulgaris (PV) on COVID-19 is not clear. We also"/>
 <result pre="also do not have data on the impact of this" exact="autoimmune disease," post="which may involve the mucous membranes, on the acquisition"/>
 <result pre="Health20202532788032052514 2ZhouFYuTDuRFanGLiuYLiuZet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="cohort study Lancet2020S0140-673620305663 3StanleyJRAmagaiMPemphigus, bullous impetigo, and the staphylococcal scalded-skin" exact="syndrome" post="N Eng J Med200635517180010 4WuHWangZHYanALyleSFakharzadehSWahlJKet al.Protection against pemphigus foliaceus"/>
 <result pre="staphylococcal scalded-skin syndrome N Eng J Med200635517180010 4WuHWangZHYanALyleSFakharzadehSWahlJKet al.Protection against" exact="pemphigus" post="foliaceus by desmoglein 3 in neonates N Eng J"/>
 <result pre="3 in neonates N Eng J Med20003431315 5KridinKZelber-SagiSBergmanRPemphigus vulgaris and" exact="pemphigus" post="foliaceus: differences in epidemiology and mortality Act Derm Venereol2017978-910959"/>
 <result pre="update Drugs20157532718425655250 8GheisariMFarajiZDadrasMSNasiriSRobatiRMMoravvejHet al.Methylprednisolone pulse therapy plus adjuvant therapy for" exact="pemphigus" post="vulgaris: an analysis of 10 years' experience on 312"/>
 <result pre="patients Dermatol Ther2019325e1305731400243 9KunisakiKMJanoffENInfluenza in immunosuppressed populations: a review of" exact="infection" post="frequency, morbidity, mortality, and vaccine responses Lancet Infect Dis20099849350419628174"/>
 <result pre="and vaccine responses Lancet Infect Dis20099849350419628174 10Shahidi-DadrasMPishgahiMTabaryMKheradmandZAraghiFDadkhahfarSet al.Cardiac function in" exact="pemphigus" post="vulgaris patients before and after steroid pulse therapy J"/>
 <result pre="Treat202015 11PishgahiMDadkhahfarSRobatiRMKheradmandZShahidi-DadrasMZargariOet al.Electrocardiographic changes after high-dose corticosteroid pulse therapy in" exact="pemphigus" post="patients J Dermatolog Treat2018298802529668335 12RussellCDMillarJEBaillieJKClinical evidence does not support"/>
 <result pre="effects PLoS Med200639e34316968120 14GuoLHanYLiJChenQRenYWuQet al.Long-term outcomes in patients with severe" exact="acute" post="respiratory syndrome treated with oseltamivir: a 12-year longitudinal study"/>
 <result pre="PLoS Med200639e34316968120 14GuoLHanYLiJChenQRenYWuQet al.Long-term outcomes in patients with severe acute" exact="respiratory" post="syndrome treated with oseltamivir: a 12-year longitudinal study Int"/>
 <result pre="Med200639e34316968120 14GuoLHanYLiJChenQRenYWuQet al.Long-term outcomes in patients with severe acute respiratory" exact="syndrome" post="treated with oseltamivir: a 12-year longitudinal study Int J"/>
 <result pre="Critical Care20192319930917856 16SinhaPChatterjeeMVasudevanBPemphigus vulgaris: A dermatological sequel of severe H1N1" exact="infection" post="Indian Dermatol Online J201452216724860767 17DidonaDMaglieREmingRHertlMPemphigus: Current and Future Therapeutic"/>
 <result pre="with short-term prednisone versus prednisone alone for the treatment of" exact="pemphigus" post="(Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial"/>
 <result pre="trial Lancet20173891008320314028342637 20ChoABradleyBKauffmanRPriyamvadaLKovalenkovYFeldmanRet al.Robust memory responses against influenza vaccination in" exact="pemphigus" post="patients previously treated with rituximab JCI insight20172129322228614800 21KasperkiewiczMEmingRBehzadMHunzelmannNMeurerMSchulzeâ€�KoopsHet al.Efficacy"/>
 <result pre="of rituximab in pemphigus: experience of the German Registry of" exact="Autoimmune" post="Diseases J Dtsch Dermatol Ges201210107273322577946 22ChiuH-YChangC-YHsiaoC-HWangL-FConcurrent cytomegalovirus and herpes"/>
 <result pre="rituximab in pemphigus: experience of the German Registry of Autoimmune" exact="Diseases" post="J Dtsch Dermatol Ges201210107273322577946 22ChiuH-YChangC-YHsiaoC-HWangL-FConcurrent cytomegalovirus and herpes simplex"/>
 <result pre="of Autoimmune Diseases J Dtsch Dermatol Ges201210107273322577946 22ChiuH-YChangC-YHsiaoC-HWangL-FConcurrent cytomegalovirus and" exact="herpes" post="simplex virus infection in pemphigus vulgaris treated with rituximab"/>
 <result pre="Diseases J Dtsch Dermatol Ges201210107273322577946 22ChiuH-YChangC-YHsiaoC-HWangL-FConcurrent cytomegalovirus and herpes simplex" exact="virus infection" post="in pemphigus vulgaris treated with rituximab and prednisolone Acta"/>
 <result pre="J Dtsch Dermatol Ges201210107273322577946 22ChiuH-YChangC-YHsiaoC-HWangL-FConcurrent cytomegalovirus and herpes simplex virus" exact="infection" post="in pemphigus vulgaris treated with rituximab and prednisolone Acta"/>
 <result pre="Dermatol Ges201210107273322577946 22ChiuH-YChangC-YHsiaoC-HWangL-FConcurrent cytomegalovirus and herpes simplex virus infection in" exact="pemphigus" post="vulgaris treated with rituximab and prednisolone Acta Derm Venereol2013932200122948546"/>
 <result pre="vulgaris treated with rituximab and prednisolone Acta Derm Venereol2013932200122948546 23WeiKWangYWangWChenWFatal" exact="infection" post="of Pneumocystis jiroveci pneumonia in a pemphigus patient treated"/>
 <result pre="and prednisolone Acta Derm Venereol2013932200122948546 23WeiKWangYWangWChenWFatal infection of Pneumocystis jiroveci" exact="pneumonia" post="in a pemphigus patient treated with rituximab J Eur"/>
 <result pre="Derm Venereol2013932200122948546 23WeiKWangYWangWChenWFatal infection of Pneumocystis jiroveci pneumonia in a" exact="pemphigus" post="patient treated with rituximab J Eur Acad Dermatol Venereol2017318e350e35128129481"/>
 <result pre="J Eur Acad Dermatol Venereol2017318e350e35128129481 24AtkinsonJRBergmannCCProtective humoral immunity in the" exact="central nervous system" post="requires peripheral CD19-dependent germinal center formation following coronavirus encephalomyelitis"/>
 <result pre="Venereol2017318e350e35128129481 24AtkinsonJRBergmannCCProtective humoral immunity in the central nervous system requires" exact="peripheral" post="CD19-dependent germinal center formation following coronavirus encephalomyelitis J Virol20179123e013521728931676"/>
 <result pre="nervous system requires peripheral CD19-dependent germinal center formation following coronavirus" exact="encephalomyelitis" post="J Virol20179123e013521728931676 25BaigAMKhaleeqAAliUSyedaHEvidence of the COVID-19 Virus Targeting the"/>
 <result pre="meta-analysis J Am Acad Dermatol20157322647126088689 27KimS-HKoJ-HParkGEChoSYHaYEKangJ-Met al.Atypical presentations of MERS-CoV" exact="infection" post="in immunocompromised hosts J Infect Chem2017231176973 28BrownAEMotaparthiKHsuSRituximab and intravenous"/>
 <result pre="Infect Chem2017231176973 28BrownAEMotaparthiKHsuSRituximab and intravenous immunoglobulin as alternatives to long-term" exact="systemic" post="corticosteroids in the treatment of pemphigus: a single center"/>
 <result pre="in China: A systematic review J Med Virol20209254799032052466 30LewTWKwekT-KTaiDEarnestALooSSinghKet al.Acute" exact="respiratory" post="distress syndrome in critically ill patients with severe acute"/>
 <result pre="A systematic review J Med Virol20209254799032052466 30LewTWKwekT-KTaiDEarnestALooSSinghKet al.Acute respiratory distress" exact="syndrome" post="in critically ill patients with severe acute respiratory syndrome"/>
 <result pre="al.Acute respiratory distress syndrome in critically ill patients with severe" exact="acute" post="respiratory syndrome JAMA200329033748012865379 31PathoulasJTStoffBKLeeKCFarahRSEthical Outpatient Dermatology Care During the"/>
 <result pre="respiratory distress syndrome in critically ill patients with severe acute" exact="respiratory" post="syndrome JAMA200329033748012865379 31PathoulasJTStoffBKLeeKCFarahRSEthical Outpatient Dermatology Care During the Coronavirus"/>
 <result pre="distress syndrome in critically ill patients with severe acute respiratory" exact="syndrome" post="JAMA200329033748012865379 31PathoulasJTStoffBKLeeKCFarahRSEthical Outpatient Dermatology Care During the Coronavirus (COVID-19)"/>
</results>
